Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Breathalyzer Test for Personalized Disease Detection

By LabMedica International staff writers
Posted on 14 Feb 2017
A novel breathalyzer device has been developed that enables detection of volatile compounds produced by respiratory viruses such as the influenza virus and other pathogenic microorganisms.

A common feature of the inflammatory response in patients who have actually contracted influenza is the generation of a number of volatile products of the alveolar and airway epithelium. More...
These products include a number of volatile organic compounds (VOCs) and nitric oxide (NO). Investigators at the University of Texas designed a portable three-sensor array microsystem-based device to detect these biomarkers, which can be used to detect the disease.

The device, which may in the future be available over-the-counter in pharmacies, resembles the breathalyzers used by police to determine alcohol levels in drivers suspected of being under the influence. The patient simply exhales into the device, which uses gas-specific semiconductor sensors to measure levels of biomarker in the breath.

"I think that technology like this is going to revolutionize personalized diagnostics. This will allow people to be proactive and catch illnesses early, and the technology can easily be used to detect other diseases, such as Ebola virus disease, simply by changing the sensors," said first author Dr. Pelagia-Irene Gouma, professor of materials science and engineering at the University of Texas. "Before we applied nanotechnology to create this device, the only way to detect biomarkers in a person's breath was through very expensive, highly-technical equipment in a lab, operated by skilled personnel. Now, this technology could be used by ordinary people to quickly and accurately diagnose illness."

The breathalyzer device was described in detail in a paper published in the January 20, 2017, online edition of the journal Sensors.


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.